Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...4748495051525354555657...5960»
  • ||||||||||  Activation of Notch Signaling in Podocytes by Growth Hormone (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_1449;    
    Blocking Notch activation with γ-secretase inhibitors ameliorates glomerular injury and proteinuria in conditions of GH-associated nephropathy. Funding Government Support - Non-U.S.
  • ||||||||||  Clinical, Journal:  Hepatic steatosis in patients with acromegaly. (Pubmed Central) -  Oct 9, 2019   
    This study shows that in patients with acromegaly, carriers of the PNPLA3 susceptibility allele are at risk of developing hepatic steatosis, as assessed by CAP. Comorbid NAFLD might compound prognosis in such patients; thus, further research into the pathomechanisms and treatment of NAFLD in acromegaly is warranted.
  • ||||||||||  Journal:  Expert document on management of acromegaly. (Pubmed Central) -  Oct 8, 2019   
    Comorbid NAFLD might compound prognosis in such patients; thus, further research into the pathomechanisms and treatment of NAFLD in acromegaly is warranted. This document is intended to solve some common clinical questions and to facilitate decision making in the management of patients with acromegaly.
  • ||||||||||  Journal:  Mixed gangliocytoma-pituitary adenoma containing GH and GHRH co-secreting adenoma cells. (Pubmed Central) -  Oct 5, 2019   
    A proposed developmental mechanism of growth hormone (GH)-secreting mixed gangliocytoma-pituitary adenoma involves GH-releasing hormone (GHRH) produced by the gangliocytic components promoting the growth of tumor including GH-secreting adenomatous components. Since our present case indicated that the adenomatous components of mixed gangliocytoma-pituitary adenoma could secrete both GH and GHRH simultaneously, progression of GH-secreting mixed gangliocytoma and pituitary adenoma may involve exposure to spontaneously produced GHRH due to the adenomatous components.
  • ||||||||||  Clinical, Journal:  Outcome of pregnancies in a large cohort of women with acromegaly. (Pubmed Central) -  Oct 2, 2019   
    Our study confirms the impact of gestation on IGF-1 levels. However, it also indicates that acromegaly still holds an increased risk for worsening of comorbidities, especially in uncontrolled patients.
  • ||||||||||  Retrospective data, Journal:  Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. (Pubmed Central) -  Sep 29, 2019   
    In naive patients with acromegaly, first-line SSA therapy is associated with a better biochemical response and greater tumor shrinkage in T2-hypointense compared to T2-hyperintense adenomas. Therefore, T2-weighted sequences of pituitary MRI can help to classify GH-secreting pituitary adenomas into a T2-hypointense and T2-hyperintense type and, therefore, to identify patients who can better respond to first-line SSA therapy.
  • ||||||||||  Biomarker, Clinical, Journal:  Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice. (Pubmed Central) -  Sep 29, 2019   
    These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator. In addition, our results suggest that the assessment of BCAAs could help to identify active disease and to monitor the response to therapeutic strategies.
  • ||||||||||  Journal:  Role of stereotactic radiosurgery in the treatment of acromegaly. (Pubmed Central) -  Sep 26, 2019   
    Factors favouring better outcomes include time from last resection to SRS, older age, peri-procedural withdrawal of medication, higher margin and maximum dose.Hypopituitarism is the most common side effects and requires yearly screening. With the new advances in the field Fractionated-stereotactic radiosurgery and cyber-knife robotic radiosurgery have been introduced with promising preliminary results..
  • ||||||||||  Clinical, Journal:  Risk category system to identify pituitary adenoma patients withmutations. (Pubmed Central) -  Sep 18, 2019   
    We propose a user-friendly risk categorisation system that can reliably group patients into high-risk, moderate-risk and low-risk groups for the presence ofmutations, thus providing guidance in identifying patients at high risk of carrying anmutation. This risk score is based on a cohort with high prevalence ofmutations and should be applied cautiously in other populations.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis
    Review, Journal:  Acromegaly. (Pubmed Central) -  Sep 18, 2019   
    Pharmacological treatments include somatostatin receptor ligands (such as octreotide, lanreotide and pasireotide), dopamine agonists and the growth hormone receptor antagonist pegvisomant. In this Primer, we review the main aspects of acromegaly, including scientific advances that underlie expanding knowledge of disease pathogenesis, improvements in disease management and new medical therapies that are available and in development to improve disease control.
  • ||||||||||  Journal:  Acromegaly. (Pubmed Central) -  Sep 18, 2019   
    In this Primer, we review the main aspects of acromegaly, including scientific advances that underlie expanding knowledge of disease pathogenesis, improvements in disease management and new medical therapies that are available and in development to improve disease control. No abstract available
  • ||||||||||  TO EVALUATE THE PULMONARY MANIFESTATIONS OF ACROMEGALY (Board #090t - Exhibition) -  Sep 17, 2019 - Abstract #WSS2019WSS_1692;    
    The incidence of OSA in acromegaly is high, and patients even with mild OSA are symptomatic. The incidence of central apnea is significantly more in acromegaly patients as compared to control.
  • ||||||||||  Somavert (pegvisomant) / Pfizer, Signifor LAR (pasireotide) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Clinical, Journal, Combination therapy:  Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. (Pubmed Central) -  Sep 15, 2019   
    The incidence of central apnea is significantly more in acromegaly patients as compared to control. Pasireotide-LAR may represent a suitable therapeutic alternative in a subset of acromegalic patients requiring combination therapy involving a 1gSRL.
  • ||||||||||  Mycapssa (octreotide) / Chiesi
    Trial primary completion date:  OPTIMAL: Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly (clinicaltrials.gov) -  Sep 14, 2019   
    P3,  N=56, Active, not recruiting, 
    Pasireotide-LAR may represent a suitable therapeutic alternative in a subset of acromegalic patients requiring combination therapy involving a 1gSRL. Trial primary completion date: Dec 2019 --> Jun 2019
  • ||||||||||  Journal:  Growth hormone controls lipolysis by regulation of FSP27 expression. (Pubmed Central) -  Sep 14, 2019   
    Furthermore, overexpression of FSP27 is sufficient to fully suppress GH-induced lipolysis and insulin resistance in cultured adipocytes. Taken together, these data decipher a molecular mechanism by which GH acutely regulates lipolysis and insulin resistance in adipocytes.
  • ||||||||||  Clinical, Retrospective data, Journal:  Machine Learning-Based Radiomics Predicts Radiotherapeutic Response in Patients With Acromegaly. (Pubmed Central) -  Sep 13, 2019   
    Decision curve analysis confirmed the clinical utility of the radiomics model. Using pre-radiotherapy clinical and MRI data, we developed a radiomics model with favorable performance for individualized non-invasive prediction of radiotherapeutic response, which may help in identifying acromegaly patients who are likely to benefit from radiotherapy.
  • ||||||||||  Journal:  Predictors of colonic pathologies in active acromegaly: single tertiary center experience. (Pubmed Central) -  Sep 12, 2019   
    Using pre-radiotherapy clinical and MRI data, we developed a radiomics model with favorable performance for individualized non-invasive prediction of radiotherapeutic response, which may help in identifying acromegaly patients who are likely to benefit from radiotherapy. The frequency of hyperplastic polyps was increased, whereas colonic malignancy was not observed in Turkish patients with active acromegaly.
  • ||||||||||  Diabetic Ketoacidosis Secondary to Acromegaly: Case Report. () -  Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1354;    
    Therapeutic options for acromegaly are transsphenoidal surgical removal of the tumor, use of medications that inhibit GH production, and reduce tumor volume such as long-acting somatostatin analogues and dopaminergic agonists, and often when there is tumor residue a second surgical intervention is attempted. After the successful treatment of acromegalics, there is recovery of euglycemia, indicating that the pancreatic function of these patients is preserved.
  • ||||||||||  Treatment of Growth Hormone Excess is Associated with Improvement in Abnormal Cardiac Phenotypes () -  Sep 9, 2019 - Abstract #HFSA2019HFSA_138;    
    sContrary to prior research, treatment of human growth hormone excess resulted in an improvement in dilated as well as hypertrophic phenotypes, though not necessarily independent of guideline-directed medical therapy. This highlights the importance of effective treatment of GH excess states in reducing the prevalent cardiovascular morbidity and mortality in patients with acromegaly.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Clinical, Journal:  Brazilian multicenter study on pegvisomant treatment in acromegaly. (Pubmed Central) -  Sep 7, 2019   
    This highlights the importance of effective treatment of GH excess states in reducing the prevalent cardiovascular morbidity and mortality in patients with acromegaly. In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    Clinical, Journal:  Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. (Pubmed Central) -  Sep 7, 2019   
    After stereo-tactic radiation therapy in combination with chemotherapy, she is currently in remission from her lymphoma and has normalized IGF-1 levels without medical therapy, 8 months after her histopathological diagnosis. This is the only reported case of its kind and displays the importance of a broad differential diagnosis, multidisciplinary evaluation, and critical intraoperative decision-making when treating atypical sellar lesions.
  • ||||||||||  temozolomide / generics
    Review, Journal:  Pituitary adenomas (Pubmed Central) -  Sep 4, 2019   
    ...The alkylating chemotherapeutic agent temozolomide is used for the first-line chemotherapy of rare aggressively growing pituitary adenomas...A new development is hypofractionated radiosurgery for protection of structures at risk. Fractionated irradiation is necessary with large radiation volumes and for pituitary adenomas with a close proximity to the optic tract.
  • ||||||||||  Journal:  Interdisciplinary Management of Sellar Masses (Pubmed Central) -  Sep 3, 2019   
    In the early postoperative period special attention to the development and treatment of disordered body water homeostasis and hypopituitarism is crucial. Interdisciplinary work-up and decision making are of utmost importance and will offer the best management.